In a postoperative CVICU patient with a newly implanted prosthetic heart valve, how should I evaluate valve function and manage anticoagulation, hemodynamics, and potential complications such as regurgitation, obstruction, or endocarditis?

Management of Valvular Issues in Postoperative CVICU Patients with Prosthetic Heart Valves

Establish baseline valve function with transthoracic echocardiography (TTE) within 6-12 weeks post-surgery to document transprosthetic gradients, ventricular function, and absence of paravalvular regurgitation—this baseline is critical for interpreting all future changes in valve function. 1

Immediate Postoperative Evaluation (First 6-12 Weeks)

Baseline Assessment Components

• Clinical assessment: Evaluate symptomatic status, physical signs, heart rhythm abnormalities, and wound healing completeness 1
• Imaging studies: Obtain chest X-ray to ensure resolution of postoperative abnormalities, ECG for rhythm assessment, and comprehensive TTE 1
• Echocardiographic parameters: Document pericardial effusion, ventricular function, prosthetic function, paravalvular regurgitation, and disease at other valve sites 1
• Laboratory testing: Perform routine hematology, biochemistry, and tests for hemolysis 1

This baseline visit is essential for patient education on endocarditis prophylaxis and anticoagulation management. 1

Anticoagulation Management

Mechanical Prosthetic Valves

All patients with mechanical valves require lifelong vitamin K antagonist (VKA) anticoagulation with INR monitoring—direct oral anticoagulants (DOACs) are contraindicated and should never be used. 1

Target INR by Valve Position and Risk Factors:

Mechanical Aortic Valve:

• INR 2.5 (range 2.0-3.0) for bileaflet or current-generation single tilting disc valves without additional risk factors 1
• INR 3.0 (range 2.5-3.5) if patient has atrial fibrillation, previous thromboembolism, LV dysfunction, hypercoagulable conditions, or older-generation mechanical valves (ball-in-cage) 1

Mechanical Mitral Valve:

• INR 3.0 (range 2.5-3.5) for all patients regardless of risk factors 1

Add aspirin 75-100 mg daily to VKA therapy in all patients with mechanical valves. 1

Bridging Anticoagulation in Early Postoperative Period:

• Initiate heparin early after surgery once postoperative bleeding is no longer an issue, continuing until INR reaches therapeutic range 1
• Use either intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH) 1
• For bridging procedures requiring VKA interruption, UFH remains the only approved heparin treatment; LMWH twice daily at therapeutic doses is an off-label alternative 1

Bioprosthetic Valves

Mitral Bioprosthesis:

• VKA anticoagulation to INR 2.5 for the first 3 months is reasonable 1

Aortic Bioprosthesis:

• Low-dose aspirin 75-100 mg daily for the first 3 months should be considered 1
• VKA anticoagulation to INR 2.5 for the first 3 months may be reasonable 1

After the initial 3-month period, aspirin 75-100 mg daily is reasonable for all patients with bioprosthetic valves. 1

Valve Repair

• VKA anticoagulation should be considered for the first 3 months after mitral valve repair 1

Prosthetic Valve Thrombosis: Recognition and Management

Clinical Suspicion

Suspect valve thrombosis in any patient with any type of prosthetic valve (mechanical or bioprosthetic) who presents with recent increase in dyspnea or fatigue, especially if there has been interrupted or subtherapeutic anticoagulation in preceding weeks. 1

Diagnostic Approach

• TTE is indicated to assess hemodynamic severity and follow resolution of valve dysfunction 1
• Transesophageal echocardiography (TEE) is indicated to assess thrombus size and valve motion 1
• Fluoroscopy or CT is reasonable to assess valve motion 1

Treatment Algorithm

For Obstructive Thrombosis in Critically Ill Patients:

• Emergency valve replacement is recommended for patients with NYHA class III-IV symptoms without serious comorbidities 1
• Immediately transfer to cardiac center with surgical facilities after giving 5000 units heparin intravenously 1

For Less Critical Presentations:

• Fibrinolytic therapy is reasonable for recent onset (<14 days) NYHA class I-II symptoms with small thrombus (<0.8 cm) 1
• Use recombinant tissue plasminogen activator 10 mg bolus + 90 mg over 90 minutes with UFH, or streptokinase 1,500,000 units over 60 minutes without UFH 1
• Fibrinolytic therapy is reasonable for thrombosed right-sided prosthetic valves 1

For Bioprosthetic Valve Thrombosis:

• Anticoagulation using VKA and/or UFH is recommended before considering reintervention 1

Hemodynamic Monitoring and Valve Function Assessment

Interpretation of Transprosthetic Gradients

Common pitfall: High transprosthetic velocity or gradient alone does not prove valve obstruction—must differentiate from prosthesis-patient mismatch (PPM), high flow states, or technical errors. 1

Stepwise Approach to High Gradients:

1. Compare measured effective orifice area (EOA) with normal reference value for the specific prosthesis type and size 1
2. If EOA is lower than normal reference AND there is decreased Doppler velocity index (DVI <0.25) with prolonged acceleration time/ejection time ratio (AT/ET >0.37), suspect prosthetic valve obstruction 1
3. If measured EOA is close to normal reference, calculate indexed EOA (EOA/BSA)—if <0.85 cm²/m², PPM is present 1
4. Serial studies showing decreasing EOA and DVI or increasing mean gradient suggest developing obstruction 1

High Flow States to Consider:

• Postoperative period, anemia, sepsis, occult mitral prosthesis regurgitation, aortic prosthetic valve regurgitation 1

Paravalvular Regurgitation

Reoperation is recommended if paravalvular leak is related to endocarditis or causes hemolysis requiring repeated blood transfusions or leading to severe symptoms. 1

Transcatheter closure may be considered for paravalvular leaks with clinically significant regurgitation in surgical high-risk patients (Heart Team decision). 1

Prosthetic Valve Endocarditis (PVE)

Risk and Prophylaxis

• Highest risk occurs in first 3-6 months after implantation, but lifelong risk remains constant 1
• Lifelong antibiotic prophylaxis is required for dental, endoscopic, and surgical procedures 1

Diagnosis and Management

Maintain high index of suspicion, particularly in elderly or vulnerable populations—Staphylococcus aureus is now the predominant organism in developed countries. 2

Diagnostic approach:

• Obtain multiple blood cultures before administering antibiotics 1
• TEE is essential due to greater sensitivity in detecting vegetations, paravalvular abscesses, or new paravalvular leak 1
• Serial TEE by experienced operator is important if initial findings are subtle or absent 1

Management:

• Immediately refer to cardiac center with cardiac surgery facilities 1
• Multidisciplinary endocarditis team approach involving cardiologists, cardiac surgeons, and microbiologists is mandatory 1, 2
• Intravenous antibiotics for 4-6 weeks, minimum 2-3 weeks after fever resolution 1

Surgical indications in PVE:

• Heart failure 1
• Valve dehiscence on fluoroscopy or echocardiography 1
• Evidence of increasing obstruction or worsening regurgitation 1
• Complications such as abscess formation 1

Ongoing Surveillance

Follow-up Schedule

• Clinical assessment yearly or sooner if new cardiac symptoms occur 1
• TTE with any new symptoms or suspected complications 1

Imaging Frequency by Valve Type:

• Mechanical valves: Baseline TTE only, then as clinically indicated 1
• Surgical bioprosthetic valves: Baseline, at 5 and 10 years, then annually 1
• Transcatheter bioprosthetic valves: Baseline and then annually 1
• Mitral valve repair: Baseline, 1 year, then every 2-3 years 1

Yearly echocardiography is recommended after the fifth year in patients with bioprostheses, and earlier in young patients to detect structural deterioration. 1

Critical Contraindications and Warnings

Never use direct oral anticoagulants (dabigatran, rivaroxaban, apixaban) in patients with mechanical prosthetic valves—this is associated with increased thrombotic and bleeding complications. 1

Relative contraindications to adding antiplatelet agents to anticoagulation include:

• Previous gastrointestinal bleeding from ulcer disease or angiodysplasia 1
• Hyper-responders to aspirin with excessively prolonged bleeding time 1
• Poorly controlled hypertension due to increased intracerebral hemorrhage risk 1